Bobby Lucero

1,2,4-Triazolo[1,5-a]pyrimidines in drug design.

K. Brunden, C. Ballatore, Killian Oukoloff, 2019, European journal of medicinal chemistry.

Evaluation of the Structure-Activity Relationship of Microtubule-Targeting 1,2,4-Triazolo[1,5-a]pyrimidines Identifies New Candidates for Neurodegenerative Tauopathies.

J. Trojanowski, V. Lee, A. Brancale, 2021, Journal of medicinal chemistry.

Structure-Activity Relationships, Tolerability and Efficacy of Microtubule-Active 1,2,4-Triazolo[1,5-a]pyrimidines as Potential Candidates to Treat Human African Trypanosomiasis

A. Brancale, C. Caffrey, K. Brunden, 2023, bioRxiv.

Microtubule-Stabilizing 1,2,4-Triazolo[1,5-a]pyrimidines as Candidate Therapeutics for Neurodegenerative Disease: Matched Molecular Pair Analyses and Computational Studies Reveal New Structure–Activity Insights

Virginia M. Y. Lee, A. Brancale, Amos B. Smith, 2022, Journal of medicinal chemistry.

Protein–protein interactions: developing small-molecule inhibitors/stabilizers through covalent strategies

C. Ballatore, Bobby Lucero, Lawrence J Liu, 2023, Trends in pharmacological sciences.

A small‐molecule microtubule‐stabilizing agent safely reduces Aβ plaque and tau pathology in transgenic mouse models of Alzheimer's disease

K. Brunden, C. Ballatore, Bobby Lucero, 2024, Alzheimer's & dementia : the journal of the Alzheimer's Association.

Carmaphycin B-Based Proteasome Inhibitors to Treat Human African Trypanosomiasis: Structure-Activity Relationship and In Vivo Efficacy.

T. Kronenberger, J. Almaliti, Bobby Lucero, 2024, ACS infectious diseases.

Clickable Probes for Pathogen Proteasomes: Synthesis and Applications

Bobby Lucero, Lawrence J Liu, Conor R. Caffrey, 2024, ACS omega.